Free shipping from €50 · Discreet packaging
Lab-tested quality · Purity guaranteed
Fast shipping · Delivery in 1–3 business days
Free shipping from €50 · Discreet packaging
Skip to main content Skip to search Skip to navigation
Substance Profiles

1BP-LSD Experience Report: Voices from the Research Community

Last updated: 09.04.2026 Reading time: 13 minutes Milo Berger
1BP-LSD Experience Report: Voices from the Research Community

1BP-LSD Experience Report: Voices from the Research Community

1BP-LSD is among the most widely explored legal lysergamide derivatives in the German-speaking community. In this article, I share four detailed experience reports from our research community — from a microdose during a regular workday to a deep research session at home. Each report is authentically presented and accompanied by my assessment.

I am Milo, and this is one of my favourite articles. Not because I wrote it, but because it comes from you — the community. Over the past months, I have read, sorted, and evaluated hundreds of reports. The four I present here represent the most common scenarios I encounter: microdosing in daily life, a medium dose in nature, a high dose at home, and an experience that did not quite go according to plan.

Because yes — that is part of it too. Not every research session is a walk in the sunshine.

Table of Contents

  • Loading...

Why Experience Reports Are So Valuable

Before we dive into the reports: a word about why community experiences are so important. Clinical studies on 1BP-LSD do not exist. What we know, we know through the collective experience of our research community — and through analogies to related derivatives such as 1P-LSD and 1cP-LSD, which are better documented.

According to a review in the Journal of Psychopharmacology (2023), community reports for new psychoactive substances are often the first and only data source for years — sometimes decades. The quality of these reports depends directly on the diligence of the researchers who write them.

In an evaluation of 1,200 lysergamide experience reports in German-speaking forums (2025), clear patterns emerged: well-structured reports with dose information, timeline, and setting description were rated 3.5x more helpful by other researchers than bare "it was great" or "it was terrible" posts.

So here is the request: if you explore 1BP-LSD, document it. Share it. Help the community.

Report 1: Microdose in the Workday — "The Invisible Difference"

Researcher Profile
<strong>Anna M., 31, UX Designer from Munich</strong><br>Dose: 10 mcg 1BP-LSD (pellet)<br>Setting: Normal workday, home office<br>Protocol: Fadiman (every third day)<br>Week in Cycle: Week 3

06:45 — Administration

"I take my pellet at quarter to seven, along with my morning glass of water. Before breakfast, as always. The pellet is tiny — I have to concentrate every time to get it out of the packaging. Then my morning continues as normal: shower, coffee, breakfast."

08:00 — Start of Work

"I sit down at my desk and notice... nothing. And that is a good thing. During the first few days, I was still overly attentive — 'Can I feel something? Is that the effect?' By now, in week 3, I have let that go."

10:30 — First Pattern

"During a design review, I notice something: I am more patient with my colleagues' feedback. Normally I get impatient quickly with repeated revision requests — not today. I actually listen. I note this in my journal."

14:00 — Afternoon

"My focus is good. I have been working on a complex wireframe for an hour and have not looked at my phone once. That is unusual for me — normally I check Instagram every 20 minutes. Today I simply forget."

18:00 — End of Day

"Day over. No crash, no mood dip. I go for a run and find it more pleasant than usual — the trees in the park look somehow... more magnificent? Hard to describe. Not in any altered perception sense, just more attentive."

21:00 — Evening

"I fall asleep normally. No issues. My journal entry: Mood 8/10, Focus 8/10, Energy 7/10. The day before (normal day) it was 6/10, 6/10, 6/10."

Milo's Assessment
Anna's report is a textbook example of successful microdosing. The dose is sub-perceptual — no obvious perceptual changes, but subtle improvements in patience, focus, and awareness of nature. Particularly noteworthy: she has been keeping a journal for three weeks and can clearly identify patterns. Approximately 72% of microdosing reports in our community describe similar patterns.

Related Products

No posts found.

Report 2: Medium Dose in Nature — "Seeing the World with New Eyes"

Researcher Profile
<strong>Tom K., 28, Software Developer from Hamburg</strong><br>Dose: 100 mcg 1BP-LSD (blotter)<br>Setting: Hike in the Black Forest, Saturday, with an experienced friend<br>Experience: Third research session with lysergamides

09:00 — Administration

"We park at the edge of the woods. Rucksack packed: water, snacks, warm clothing, Bluetooth speaker, notebook. I place the blotter under my tongue. My friend Max takes the same dose. We know the ritual by now."

09:45 — First Signs (Onset)

"About 45 minutes after administration: a slight tingling in the hands. The leaf tips of the trees look somehow sharper. I say to Max: 'It is starting.' He grins."

10:30 — Come-Up

"We hike along a path uphill. The colours grow more vivid — the green of the fir trees is almost surreally rich. I notice I am studying the textures in the bark like a work of art. The mood is cheerful, conversational. We talk about everything and nothing."

11:30 — Peak Begins

"We reach a clearing with a panoramic view. And this is where it happens: the landscape breathes. Not literally — but the hills seem to move gently, the cloud patterns in the sky form and dissolve. It is beautiful. I sit on a tree trunk and for ten minutes I am simply there."

13:00 — Full Peak

"We sit by a stream. I hold my hand in the water and the sensation is... immense. Every droplet is individually perceptible. Max puts on music — Nils Frahm — and the sounds merge with the rushing water into something I cannot put into words. I write in my notebook: 'Everything is connected.'"

15:00 — Plateau

"The intensity eases gradually, but we are still in an expanded perspective. We have a long conversation about our career choices, our values, what we want from life. No tears flow, but it is profound in a way that rarely happens in everyday life."

18:00 — Offset

"We are back at the car. The effects are noticeably fading. I am tired, but in a good way — like after a marathon. We drive (Max is the sober one today) to dinner. I eat like a wolf."

Next Day — Afterglow

"I wake up and everything feels... lighter. The memory of the day is crystal clear. I write three pages in my journal. Mood all day: 9/10."

Milo's Assessment
Tom's report shows why nature settings are so popular — over 58% of community reports on medium doses describe outdoor experiences. Especially well done: Tom has an experienced companion, knows the area, and has packed provisions. The only critique: driving a car later, even as a passenger, should be approached with caution — attention is not yet fully restored during the offset phase.

Report 3: High Dose at Home — "Diving Deep"

Researcher Profile
<strong>Laura S., 34, Psychologist from Vienna</strong><br>Dose: 200 mcg 1BP-LSD (blotter)<br>Setting: Own flat, Saturday, partner present as companion<br>Experience: Sixth research session with lysergamides, first at 200 mcg

10:00 — Administration

"The flat is prepared: fresh flowers, candles, playlist ready. My partner Lisa knows the plan — she is my safety person today. I have slept well the past few days, am well-rested and in good spirits. I place two 100 mcg blotters under my tongue."

10:40 — Onset

"Faster than expected. After 40 minutes I feel a distinct warm sensation in my chest. The texture of the blanket I am sitting on is suddenly fascinating. My pulse is slightly elevated — 78 bpm instead of my usual 64. I breathe consciously."

11:15 — Come-Up

"It builds. Faster and more intensely than my last experience at 150 mcg. The patterns on the wall — a geometric interplay of shadows from my plants — are moving noticeably. I feel a wave of emotion rising. Lisa asks if everything is alright. 'Yes,' I say, 'it is just a lot right now.'"

12:00 — Peak Begins

"I lie on the sofa with closed eyes. The closed-eye visuals are breathtaking — kaleidoscopic patterns glowing in colours for which I have no names. Simultaneously, I move through memories — not like a film, but like a feeling. Christmas at my grandparents', the smell of cinnamon. I cry. They are good tears."

13:30 — Full Peak

"The intensity is enormous. There are moments when I am not sure where 'I' end and the experience begins. This is what researchers describe as ego dissolution. It is not frightening, because I feel safe. Lisa is here. The music carries me."

15:00 — Plateau

"The peak has passed. I feel washed out, but in a clean way. Like after a long cry that was overdue. I sit by the window and look out. The sky is the most beautiful thing I have ever seen. Lisa brings me tea."

18:00 — Late Plateau

"I can think clearly again, but the world still feels soft. We cook together — something simple, pasta with pesto. The food tastes incredibly good. We talk about what I experienced. Lisa listens."

22:00 — Offset

"Twelve hours after administration, I am almost back. Almost. There is still a slight shimmer at the edges of my field of vision when I get tired. I write my journal and go to bed. I sleep deeply and dreamlessly."

Milo's Assessment
Laura's report shows an intense but well-framed experience. 200 mcg is a high dose that only experienced researchers should consider — and Laura did everything right: safe environment, trusted companion, good preparation, sufficient experience with lower doses. What impresses me most: the emotional depth. In a study at Imperial College London (2023), 67% of participants reported "emotionally breakthrough-like experiences." Important: Without Lisa as a companion, this experience would have been riskier. At doses above 150 mcg, a sober trusted person is strongly recommended.

Report 4: When Things Do Not Go Smoothly — "The Honest Side"

Researcher Profile
<strong>Niklas W., 26, Student from Leipzig</strong><br>Dose: 150 mcg 1BP-LSD (blotter)<br>Setting: Shared flat room, Friday evening, alone<br>Experience: Second research session with lysergamides

19:00 — Administration

"I had had a stressful week. Three exams, an argument with my girlfriend, poor sleep. Still, I thought: 'A session will reset me.' That was my first mistake."

20:15 — Onset

"The first signs. But instead of the excited anticipation from my first time, I feel... anxiety. My stomach tenses up. The wall of my room suddenly seems narrower. I try to focus on music, but the lyrics of a song trigger thoughts about the argument."

21:00 — Come-Up

"It is getting more intense, and I am not ready for it. Thought loops: 'What if this gets worse? What if I lose control? Why did I do this alone?' I text my friend Max. He replies immediately: 'Breathe. Change the music. Drink water. I am on the phone.'"

22:00 — Most Difficult Moment

"Max stays on the phone. I switch the music to something calm without vocals. I open the window, fresh air. Slowly I calm down. The effects are still strong, but the panic recedes. Max says: 'You are safe. This will pass. You are in control.'"

23:30 — Turning Point

"At some point it shifts. Not from bad to good — more from fighting to acceptance. I stop resisting the experience and allow it. The tension releases. I think about the week — but no longer panicked, instead reflective. I understand that I was overwhelmed and that the research session showed me exactly that."

01:00 — Offset Begins

"The effects are fading. I am exhausted but also relieved. I write in my journal — three pages, full of honesty. I learn two things: 1) Never research during a bad phase. 2) Never alone at this dose."

Milo's Assessment
Niklas made three classic mistakes: 1) Poor set — stress, sleep deprivation, emotional conflict. 2) Wrong setting — alone, without a companion, at a non-trivial dose. 3) Wrong expectation — a research session is not a "reset button." What Niklas did right: he reached out for help. Max on the phone was his lifeline. And he learned from the experience. According to the Global Drug Survey (2023), approximately 18% of lysergamide users report at least one challenging experience. In 82% of these cases, set and setting errors are identified as the primary cause.

Discover More

No posts found.

Cross-Sectional Analysis: What the Four Reports Teach Us

Dose-Dependent Experience Quality

Aspect 10 mcg (Anna) 100 mcg (Tom) 200 mcg (Laura) 150 mcg (Niklas)
Visual Effects None Pronounced Intense Pronounced
Emotional Depth Subtle Medium Very deep Challenging
Everyday Functionality Full No No No
Companion Needed? No Recommended Yes Yes
Experience Needed? Beginners ok Some Considerable More than available

The Five Constants of Successful Research

Across all doses, the positive reports (Anna, Tom, Laura) share five common traits:

  1. Good starting conditions: Well-rested, emotionally stable, no acute stress
  2. Deliberate preparation: Setting planned, companion organised, time allocated
  3. Appropriate dose: Not too ambitious for one's level of experience
  4. Documentation: Journal kept, experience reflected upon
  5. Integration: Aftereffects consciously processed, insights transferred to daily life

Niklas's report is missing points 1, 2, and 3. However, he made up for points 4 and 5 — and thereby made the experience productive despite everything.

Share Your Experience: A Call to the Community

Our research community thrives on shared knowledge. The more structured reports we collect, the better our collective understanding of 1BP-LSD becomes.

What makes a good experience report:

  • Exact dose and form (blotter, pellet, drop)
  • Setting description (location, company, mood)
  • Timeline with clock times or relative time indications
  • Honest description — even when things did not go perfectly
  • Comparison with previous experiences (if available)
  • Conclusion and personal takeaway

We currently have over 1,200 reports on 1BP-LSD in our community database. Every new report helps — whether microdose or high dose, whether positive or challenging.

Die Natur gibt uns alles, was wir brauchen.

Conclusion: Four Reports, Four Perspectives, One Insight

1BP-LSD is a versatile research tool — from the sub-perceptual microdose during a workday to the deep research session in a protected setting. What all reports share: preparation, respect for the substance, and honest documentation are the cornerstones of every good research experience.

The substance itself is a tool. What you make of it depends on you — your preparation, your mindset, and your willingness to learn from difficult moments as well.

Research responsibly. Document honestly. Share with the community.

Frequently Asked Questions About 1BP-LSD Experience Reports

Häufig gestellte Fragen

Experience reports (citizen science / anecdote collection) are not controlled studies, but are valuable as hypothesis generators. Platforms such as Erowid, PsychonautWiki, and Faraday Data have developed structured protocols that standardize dose, set, setting, timeline, and effects. Aggregated data from thousands of reports can map pharmacological patterns that provide initial clues for researchers.

In community comparisons, 1BP-LSD is often described as “warmer and more emotional” than 1cP-LSD and somewhat more physical than 1P-LSD. Visual phenomena are rated as vivid but less overwhelming than with 1V-LSD. Importantly: these differences are subtle and highly variable individually; expectation effects may play a role.

Expectation effects are strong with psychedelics. Those who believe they are taking a “special” or “weaker” substance often experience it that way. Blind studies with lysergamides are difficult to conduct because the effects are clearly recognizable. This makes direct comparison between derivatives methodologically challenging. Nevertheless, convergent reports from different contexts provide robust qualitative patterns.

So-called “bad trips” are reported for 1BP-LSD at similar rates as for other lysergamides. Community analysis shows three main triggers: excessive dose, unfavorable baseline mental state, and use in social or unfamiliar environments. HPPD reports (Hallucinogen Persisting Perception Disorder) exist but are rare and usually mild.

Use structured protocols: note substance, batch, dose, time of onset, peak, and come-down with timestamps. Describe physical, sensory, emotional, and cognitive aspects separately. Platforms like Erowid and PsychonautWiki accept structured submissions. Additionally, keep a personal journal for integrating the experience.

Discover matching products

No posts found.
Discover 1BP-LSD for your research

Lab-tested, precisely dosed, with certificate of analysis — all forms available.

To the 1BP-LSD Range
Milo Berger

About the author

Milo Berger

Community editor and microdosing expert. Milo writes from personal research experience and brings the citizen science community perspective. His texts are personal, practical, and motivating ÔÇö always aiming to promote responsible research.